Compare IRIX & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRIX | NRSN |
|---|---|---|
| Founded | 1989 | 2017 |
| Country | United States | Israel |
| Employees | N/A | 15 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.8M | 28.4M |
| IPO Year | 1996 | N/A |
| Metric | IRIX | NRSN |
|---|---|---|
| Price | $1.30 | $0.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 42.8K | ★ 134.0K |
| Earning Date | 04-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.47 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,593,000.00 | N/A |
| Revenue This Year | $9.61 | N/A |
| Revenue Next Year | $8.12 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.78 | $0.68 |
| 52 Week High | $1.65 | $2.60 |
| Indicator | IRIX | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 44.87 | 43.17 |
| Support Level | $1.04 | $0.68 |
| Resistance Level | $1.54 | $1.30 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 35.85 | 12.18 |
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.